Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin for Complicated Bacteremia or Infective Endocarditis
NCT03148756Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- May 2017
- Primary completion
- Aug 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Bacteremia and infective endocarditis (IE) comparing Dalbavancin with Standard of Care (2 arms). Primary endpoint: Clinical Response at Day 84. Started May 2017; status: terminated.
02
Drugs
dalbavancin
03
Conditions
Bacteremiainfective endocarditis (IE)
Beyond the preview
Go deeper on NCT03148756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03148756.